Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 May 30;14(5):2548-2552.
doi: 10.21037/tcr-2024-2569. Epub 2025 May 13.

Novel combinations with programmed cell death 1 inhibitor for incurable recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC): is cabozantinib a front runner?

Priyanka Bhateja  1 , Marcelo Bonomi  1 , Claire Verschraegen  1
Affiliations
Editorial

Novel combinations with programmed cell death 1 inhibitor for incurable recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC): is cabozantinib a front runner?

Priyanka Bhateja et al. Transl Cancer Res. .
No abstract available

Keywords: Metastatic; cabozantinib; head and neck cancer; pembrolizumab; recurrent.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2024-2569/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394:1915-28. 10.1016/S0140-6736(19)32591-7 - DOI - PubMed
    1. Scirocchi F, Napoletano C, Pace A, et al. Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib. Front Oncol 2021;11:755433. 10.3389/fonc.2021.755433 - DOI - PMC - PubMed
    1. Saba NF, Chaudhary R, Kirtane K, et al. Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis. Clin Cancer Res 2024;30:4601-8. 10.1158/1078-0432.CCR-24-1202 - DOI - PMC - PubMed
    1. Saba NF, Steuer CE, Ekpenyong A, et al. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat Med 2023;29:880-7. 10.1038/s41591-023-02275-x - DOI - PMC - PubMed
    1. Fasano M, Corte CMD, Liello RD, et al. Immunotherapy for head and neck cancer: Present and future. Crit Rev Oncol Hematol 2022;174:103679. 10.1016/j.critrevonc.2022.103679 - DOI - PubMed